Senolytics
Human evidence and active trials are visible in this field
198 human-evidence records · 12 active trials · 872 visible funding records · 7,604 universities
Longevity Patent Family
Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker
Source-linked patent metadata for Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- AU2026205448A1
- Earliest priority
- February 1, 2019
- Latest publication
- September 17, 2026
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
CAR-T targeting senescent cells
Patent activity is ahead of evidence currently visible in the index
0 human-evidence records · 0 active trials · 0 visible funding records · 4,299 universities
Organizations named in this family
Topics connected by metadata
Senolytics88% metadata match
CAR-T targeting senescent cells80% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 3
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →